Azin Aghamajidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Azin Aghamajidi has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Xianxin Hua
Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
5 shared publications - Xuyao Zhang
Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, China
5 shared publications - Yuan Wu
Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publications - Zhicheng Peng
Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
5 shared publications - Zijie Feng
Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
5 shared publications - Amarnath Rambhatla
Vattikuti Urology Institute, Henry Ford Health
3 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Gastrointestinal cancers (GIC), including gastric cancers and colorectal cancers, are among the leading causes of cancer-related deaths worldwide. Metastatic gastric cancers and colorectal cancers often develop resistance or fail to respond to current therapies. Adoptive T-cell immunotherapy, especially with T cells expressing chimeric antigen receptors (CAR) targeting CD19, has revolutionized leukemia treatment. However, the development of CAR T-cell therapy for GICs is still in progress. In this study, we used a sequentially tumor-selected antibody and antigen retrieval system to isolate a nanobody that directs CAR T cells to attack gastrointestinal tumor cells in preclinical mouse models. The nanobody VHHB30 specifically binds to the N-terminal (nonglycosylated) domain of carcinoembryonic antigens (CEA). The resulting VHHB30-CAR T cells (CEACAR T cells) exhibited cytotoxicity against both colorectal cancer and gastric cancer cell lines in vitro in a CEA-dependent manner. Moreover, third-generation CEACAR T cells showed enhanced antitumor activity compared with second-generation CEACAR T cells. Furthermore, in vivo studies demonstrated that the CEACAR T cells eradicated various colorectal and gastric tumor xenografts in preclinical mouse models, highlighting a promising approach for CAR T-cell therapy development in GICs through unbiased in vivo selection of potent VHH binders.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Gastrointestinal cancers (GIC), including gastric cancers and colorectal cancers, are among the leading causes of cancer-related deaths worldwide. Metastatic gastric cancers and colorectal cancers often develop resistance or fail to respond to current therapies. Adoptive T-cell immunotherapy, especially with T cells expressing chimeric antigen receptors (CAR) targeting CD19, has revolutionized leukemia treatment. However, the development of CAR T-cell therapy for GICs is still in progress. In this study, we used a sequentially tumor-selected antibody and antigen retrieval system to isolate a nanobody that directs CAR T cells to attack gastrointestinal tumor cells in preclinical mouse models. The nanobody VHHB30 specifically binds to the N-terminal (nonglycosylated) domain of carcinoembryonic antigens (CEA). The resulting VHHB30-CAR T cells (CEACAR T cells) exhibited cytotoxicity against both colorectal cancer and gastric cancer cell lines in vitro in a CEA-dependent manner. Moreover, third-generation CEACAR T cells showed enhanced antitumor activity compared with second-generation CEACAR T cells. Furthermore, in vivo studies demonstrated that the CEACAR T cells eradicated various colorectal and gastric tumor xenografts in preclinical mouse models, highlighting a promising approach for CAR T-cell therapy development in GICs through unbiased in vivo selection of potent VHH binders.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Supplemental Figure 1. The nucleotide sequence (A) and amino acid residue sequence (B) of nanobody VHHB30.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Supplemental Figure 1. The nucleotide sequence (A) and amino acid residue sequence (B) of nanobody VHHB30.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Supplemental Table 1: Overview of Clinical Trials Investigating CEA-Targeted CAR T-cell Therapies in CEA-Positive Gastrointestinal and Solid Tumors
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Supplemental Table 1: Overview of Clinical Trials Investigating CEA-Targeted CAR T-cell Therapies in CEA-Positive Gastrointestinal and Solid Tumors
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Supplemental Figure 2. Proliferation and of VHHB30 3rd Generation CAR T Cells in Co-Culture with NB4/NB4CEA Tumor Cells. A. The CAR positivity of VHHB30 third-generation CAR T-cells. B. Total CD3 positive T cells increased 7days after co-culture with VHHHB30 third-generation CAR T-cells while not much in comparison to co-culture with NB4 wild type. C, D. The UTD and CAR T-cells proliferating in coculture with target NB4CEA tumor cells, while the cells decreased in other groups indicating the antigen-dependent stimulation effect of the immune synapse between CAR T-cells and its target. E. NB4CEA tumor cell numbers as a CD33 positive cell population decreased in co-culture with VHHHB30 third-generation CAR T-cells after day 2 indicating the cytotoxicity effect of VHHHB30 third-generation CAR T-cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Supplemental Figure 2. Proliferation and of VHHB30 3rd Generation CAR T Cells in Co-Culture with NB4/NB4CEA Tumor Cells. A. The CAR positivity of VHHB30 third-generation CAR T-cells. B. Total CD3 positive T cells increased 7days after co-culture with VHHHB30 third-generation CAR T-cells while not much in comparison to co-culture with NB4 wild type. C, D. The UTD and CAR T-cells proliferating in coculture with target NB4CEA tumor cells, while the cells decreased in other groups indicating the antigen-dependent stimulation effect of the immune synapse between CAR T-cells and its target. E. NB4CEA tumor cell numbers as a CD33 positive cell population decreased in co-culture with VHHHB30 third-generation CAR T-cells after day 2 indicating the cytotoxicity effect of VHHHB30 third-generation CAR T-cells.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Gastrointestinal cancers (GIC), including gastric cancers and colorectal cancers, are among the leading causes of cancer-related deaths worldwide. Metastatic gastric cancers and colorectal cancers often develop resistance or fail to respond to current therapies. Adoptive T-cell immunotherapy, especially with T cells expressing chimeric antigen receptors (CAR) targeting CD19, has revolutionized leukemia treatment. However, the development of CAR T-cell therapy for GICs is still in progress. In this study, we used a sequentially tumor-selected antibody and antigen retrieval system to isolate a nanobody that directs CAR T cells to attack gastrointestinal tumor cells in preclinical mouse models. The nanobody VHHB30 specifically binds to the N-terminal (nonglycosylated) domain of carcinoembryonic antigens (CEA). The resulting VHHB30-CAR T cells (CEACAR T cells) exhibited cytotoxicity against both colorectal cancer and gastric cancer cell lines in vitro in a CEA-dependent manner. Moreover, third-generation CEACAR T cells showed enhanced antitumor activity compared with second-generation CEACAR T cells. Furthermore, in vivo studies demonstrated that the CEACAR T cells eradicated various colorectal and gastric tumor xenografts in preclinical mouse models, highlighting a promising approach for CAR T-cell therapy development in GICs through unbiased in vivo selection of potent VHH binders.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Gastrointestinal cancers (GIC), including gastric cancers and colorectal cancers, are among the leading causes of cancer-related deaths worldwide. Metastatic gastric cancers and colorectal cancers often develop resistance or fail to respond to current therapies. Adoptive T-cell immunotherapy, especially with T cells expressing chimeric antigen receptors (CAR) targeting CD19, has revolutionized leukemia treatment. However, the development of CAR T-cell therapy for GICs is still in progress. In this study, we used a sequentially tumor-selected antibody and antigen retrieval system to isolate a nanobody that directs CAR T cells to attack gastrointestinal tumor cells in preclinical mouse models. The nanobody VHHB30 specifically binds to the N-terminal (nonglycosylated) domain of carcinoembryonic antigens (CEA). The resulting VHHB30-CAR T cells (CEACAR T cells) exhibited cytotoxicity against both colorectal cancer and gastric cancer cell lines in vitro in a CEA-dependent manner. Moreover, third-generation CEACAR T cells showed enhanced antitumor activity compared with second-generation CEACAR T cells. Furthermore, in vivo studies demonstrated that the CEACAR T cells eradicated various colorectal and gastric tumor xenografts in preclinical mouse models, highlighting a promising approach for CAR T-cell therapy development in GICs through unbiased in vivo selection of potent VHH binders.
- Open Access
- 29 April 2023
- Published by Springer Nature in Archives of Virology
- Vol. 168 (5) , 1-13
B lymphocytes in COVID-19: a tale of harmony and discordance
B lymphocytes play a vital role in the human defense against viral infections by producing specific antibodies. They are also critical for the prevention of infectious diseases by vaccination, and their activation influences the efficacy of the vaccination. Since the beginning of coronavirus disease 2019 (COVID-19), which became the main concern of the world health system, many efforts have been made to treat and prevent the disease. However, for the development of successful therapeutics and vaccines, it is necessary to understand the interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and the immune system. The innate immune system provides primary and nonspecific defense against the virus, but within several days after infection, a virus-specific immune response is provided first by antibody-producing B cells, which are converted after the resolution of disease to memory B cells, which provide long-term immunity. Although a failure in B cell activation or B cell dysfunction can cause a severe form of the disease and also lead to vaccination inefficiency, some individuals with B cell immunodeficiency have shown less production of the cytokine IL-6, resulting in a better disease outcome. In this review, we present the latest findings on the interaction between SARS-CoV-2 and B lymphocytes during COVID-19 infection.
- 29 April 2023
- Published by Springer Nature in Archives of Virology
- Vol. 168 (5) , 1-13
Open AccessB lymphocytes in COVID-19: a tale of harmony and discordance
B lymphocytes play a vital role in the human defense against viral infections by producing specific antibodies. They are also critical for the prevention of infectious diseases by vaccination, and their activation influences the efficacy of the vaccination. Since the beginning of coronavirus disease 2019 (COVID-19), which became the main concern of the world health system, many efforts have been made to treat and prevent the disease. However, for the development of successful therapeutics and vaccines, it is necessary to understand the interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and the immune system. The innate immune system provides primary and nonspecific defense against the virus, but within several days after infection, a virus-specific immune response is provided first by antibody-producing B cells, which are converted after the resolution of disease to memory B cells, which provide long-term immunity. Although a failure in B cell activation or B cell dysfunction can cause a severe form of the disease and also lead to vaccination inefficiency, some individuals with B cell immunodeficiency have shown less production of the cytokine IL-6, resulting in a better disease outcome. In this review, we present the latest findings on the interaction between SARS-CoV-2 and B lymphocytes during COVID-19 infection.
- Top Cited PapersOpen Access
- 1 January 2023
- Published by XMLink in The World Journal of Men's Health
- Vol. 41 (2) , 289-310
Impact of Varicocele Repair on Semen Parameters in Infertile Men: A Systematic Review and Meta-Analysis
Agarwal A, et al. World J Mens Health. 2022 Oct;40:e70. https://doi.org/10.5534/wjmh.220142
- 1 January 2023
- Published by XMLink in The World Journal of Men's Health
- Vol. 41 (2) , 289-310
Top Cited PapersOpen AccessImpact of Varicocele Repair on Semen Parameters in Infertile Men: A Systematic Review and Meta-Analysis
Agarwal A, et al. World J Mens Health. 2022 Oct;40:e70. https://doi.org/10.5534/wjmh.220142
- 30 October 2022
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 21 (5) , 561-573
Molecular Characteristics of Bladder Tumor: Increased Gene Expression of MAGE-A6 and MAGE-A11 with Decreased MicroRNA-34a and MicroRNA-125b
Bladder cancer is recognized as one of the top ten most common cancers worldwide. Activation of oncogenes, inactivation of tumor suppressor genes, and dysregulation of androgen signaling pathways are three major pathophysiological causes in the development of bladder tumors. Discovering potential biomarkers is required for the management and immunotherapy of bladder cancer. Melanoma-associated antigen (MAGE)-A6 and MAGE-A11 are two cancer-testis antigens that are potential coregulators of androgen receptors. MicroRNAs, especially miR-34a and miR-125b are two important tumor suppressors that play a critical role in regulating different signaling pathways and inhibiting tumor development. Twenty-nine surgical tissue biopsies were collected from patients with no preoperative chemotherapy or radiotherapy (26 males and, 3 females, mean age±SD: 62.4±13.3 years). Seventeen adjacent uninvolved tissues with no abnormalities upon histological examination were considered normal controls (14 males and, 3 females, mean age±SD: 64.2±7.4 years) . Quantitative PCR was performed to evaluate the gene expression level of MAGE-A6, MAGE-A11, miR-34a, and miR-125b in bladder cancer biopsies. MAGE-A6 and MAGE-A11 expressions were significantly increased in bladder tumors compared with normal tissues. However, the expression levels of miR-34a and miR-125b were significantly downregulated in bladder tumor tissues. Interestingly, the expression level of all these genes was significantly associated with tumor grade, pathological stage (pT), and muscular invasion. MAGE-A6 and MAGE-A11 can be considered potential markers for the diagnosis and immunotherapy of bladder tumors. Furthermore, the modulation of miR-34a and miR-125b gene expression in association with increased MAGE-A6 and MAGE-A11 genes could open a new horizon in the improvement of bladder cancer.
- 30 October 2022
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 21 (5) , 561-573
Molecular Characteristics of Bladder Tumor: Increased Gene Expression of MAGE-A6 and MAGE-A11 with Decreased MicroRNA-34a and MicroRNA-125b
Bladder cancer is recognized as one of the top ten most common cancers worldwide. Activation of oncogenes, inactivation of tumor suppressor genes, and dysregulation of androgen signaling pathways are three major pathophysiological causes in the development of bladder tumors. Discovering potential biomarkers is required for the management and immunotherapy of bladder cancer. Melanoma-associated antigen (MAGE)-A6 and MAGE-A11 are two cancer-testis antigens that are potential coregulators of androgen receptors. MicroRNAs, especially miR-34a and miR-125b are two important tumor suppressors that play a critical role in regulating different signaling pathways and inhibiting tumor development. Twenty-nine surgical tissue biopsies were collected from patients with no preoperative chemotherapy or radiotherapy (26 males and, 3 females, mean age±SD: 62.4±13.3 years). Seventeen adjacent uninvolved tissues with no abnormalities upon histological examination were considered normal controls (14 males and, 3 females, mean age±SD: 64.2±7.4 years) . Quantitative PCR was performed to evaluate the gene expression level of MAGE-A6, MAGE-A11, miR-34a, and miR-125b in bladder cancer biopsies. MAGE-A6 and MAGE-A11 expressions were significantly increased in bladder tumors compared with normal tissues. However, the expression levels of miR-34a and miR-125b were significantly downregulated in bladder tumor tissues. Interestingly, the expression level of all these genes was significantly associated with tumor grade, pathological stage (pT), and muscular invasion. MAGE-A6 and MAGE-A11 can be considered potential markers for the diagnosis and immunotherapy of bladder tumors. Furthermore, the modulation of miR-34a and miR-125b gene expression in association with increased MAGE-A6 and MAGE-A11 genes could open a new horizon in the improvement of bladder cancer.
- Open Access
- 27 October 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-12
Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy
Oncoviruses, known as cancer-causing viruses, are typically involved in cancer progression by inhibiting tumor suppressor pathways and uncontrolled cell division. Myeloid cells are the most frequent populations recruited to the tumor microenvironment (TME) and play a critical role in cancer development and metastasis of malignant tumors. Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), tumor-associated dendritic cells (TADCs), and tumor-associated neutrophils (TANs) exert different states from anti-tumorigenic to pro-tumorigenic phenotypes in TME. Although their role in the anti-tumorigenic state is well introduced, their opposing roles, pro-tumorigenic activities, such as anti-inflammatory cytokine and reactive oxygen species (ROS) production, should not be ignored since they result in inflammation, tumor progression, angiogenesis, and evasion. Since the blockade of these cells had promising results against cancer progression, their inhibition might be helpful in various cancer immunotherapies. This review highlights the promoting role of tumor-associated myeloid cells (TAMCs) in the pathophysiology of human virus tumorigenesis.
- 27 October 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-12
Open AccessTumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy
Oncoviruses, known as cancer-causing viruses, are typically involved in cancer progression by inhibiting tumor suppressor pathways and uncontrolled cell division. Myeloid cells are the most frequent populations recruited to the tumor microenvironment (TME) and play a critical role in cancer development and metastasis of malignant tumors. Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), tumor-associated dendritic cells (TADCs), and tumor-associated neutrophils (TANs) exert different states from anti-tumorigenic to pro-tumorigenic phenotypes in TME. Although their role in the anti-tumorigenic state is well introduced, their opposing roles, pro-tumorigenic activities, such as anti-inflammatory cytokine and reactive oxygen species (ROS) production, should not be ignored since they result in inflammation, tumor progression, angiogenesis, and evasion. Since the blockade of these cells had promising results against cancer progression, their inhibition might be helpful in various cancer immunotherapies. This review highlights the promoting role of tumor-associated myeloid cells (TAMCs) in the pathophysiology of human virus tumorigenesis.
- Open Access
The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
Gut microbiota can have opposing functions from pro-tumorigenic to anti-tumorigenic effects. Increasing preclinical and clinical evidence suggests that the intestinal microbiota affects cancer patients’ response to immune checkpoint inhibitors (ICIs) immunotherapy, such as anti-programmed cell death protein 1 (PD-1) and its ligand (PD-L1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Microbiota-induced inflammation possibly contributes to tumor growth and cancer development. Microbiota-derived metabolites can also be converted to carcinogenic agents related to genetic mutations and DNA damage in organs such as the colon. However, other attributes of microbiota, such as greater diversity and specific bacterial species and their metabolites, are linked to better clinical outcomes and potentially improved anti-tumor immunity. In addition, the intratumoral microbial composition strongly affects T-cell-mediated cytotoxicity and anti-tumor immune surveillance, adding more complexity to the cancer-microbiome-immune axis. Despite the emerging clinical evidence for the activity of the gut microbiota in immuno-oncology, the fundamental mechanisms of such activity are not well understood. This review provides an overview of underlying mechanisms by which the gut microbiota and its metabolites enhance or suppress anti-tumor immune responses. Understanding such mechanisms allows for better design of microbiome-specific treatment strategies to improve the clinical outcome in cancer patients undergoing systemic therapy.
Open AccessThe Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
Gut microbiota can have opposing functions from pro-tumorigenic to anti-tumorigenic effects. Increasing preclinical and clinical evidence suggests that the intestinal microbiota affects cancer patients’ response to immune checkpoint inhibitors (ICIs) immunotherapy, such as anti-programmed cell death protein 1 (PD-1) and its ligand (PD-L1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Microbiota-induced inflammation possibly contributes to tumor growth and cancer development. Microbiota-derived metabolites can also be converted to carcinogenic agents related to genetic mutations and DNA damage in organs such as the colon. However, other attributes of microbiota, such as greater diversity and specific bacterial species and their metabolites, are linked to better clinical outcomes and potentially improved anti-tumor immunity. In addition, the intratumoral microbial composition strongly affects T-cell-mediated cytotoxicity and anti-tumor immune surveillance, adding more complexity to the cancer-microbiome-immune axis. Despite the emerging clinical evidence for the activity of the gut microbiota in immuno-oncology, the fundamental mechanisms of such activity are not well understood. This review provides an overview of underlying mechanisms by which the gut microbiota and its metabolites enhance or suppress anti-tumor immune responses. Understanding such mechanisms allows for better design of microbiome-specific treatment strategies to improve the clinical outcome in cancer patients undergoing systemic therapy.